Announcements
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced the dosing of its first patient with AVD-104 in its Phase 2 SIGLEC Trial today by Ashkan Abbey, MD of Texas Retina Associates…
Read More
Favorable long-term, open-label treatment data from nearly 500 patients in real-world setting suggest that patient-tailored, as-needed administrations of fasedienol over time were safe and well-tolerated Positive exploratory fasedienol efficacy data measured by the Liebowitz Social Anxiety Scale (LSAS) demonstrated clinically meaningful reductions in fear, anxiety and avoidance of anxiety-provoking social and performance situations in daily…
Read MoreSummit Therapeutics is Currently Enrolling in a Phase III Study with Additional Phase III Study Planned for Third Quarter 2023 for Ivonescimab Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be…
Read More
The study will build upon previous studies conducted by Ghosh and her collaborators that have explored the ways social inequality contribute to unequal cancer control outcomes Excerpt from the Press Release: n January of this year, Debarchana (Debs) Ghosh, associate professor in the Department of Geography in the College of Liberal Arts and Sciences (CLAS)…
Read More
Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with a Profile that Strongly Supports Further Clinical Development Efforts AX-158 is Being Developed for Once Daily Oral Dosing to Address Autoimmune Diseases by Providing Immunomodulation without Immunosuppression Excerpt from the Press Release: CAMBRIDGE, Mass., June 1, 2023 /PRNewswire/ — Artax Biopharma, Inc., a…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuning™ antibody therapeutics that enhance the body’s antitumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced today that PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on macrophages 1), was well-tolerated with signals…
Read More
Meet with Christopher Kata, Director of Sales & Marketing and the TrialStat Team on June 25th – 29th! Christopher Kata, Director of Sales & Marketing905 [email protected] When: June 25th – June 29th 2023Where: Boston, MARegistration: DIA Global Annual Meeting 2023 It’s hard to believe an entire year has gone by and we’re ready to meet…
Read More
Excerpt from the Press Release: eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced positive interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in patients with ER+ metastatic breast cancer (mBC).…
Read More
Excerpt from the Press Release: Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today announced the data from its Phase 1 dose-escalation clinical trial of BDC-1001 that will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held at McCormick Place in Chicago, Illinois and virtually from June 2-6,…
Read More
Excerpt from the Press Release: A paralysed man has regained the ability to walk smoothly using only his thoughts for the first time, researchers said on Wednesday, thanks to two implants that restored communication between brain and spinal cord. The patient Gert-Jan, who did not want to reveal his surname, said the breakthrough had given…
Read More